首页> 美国卫生研究院文献>Marine Drugs >Perna canaliculus Lipid Complex PCSO-524™ Demonstrated Pain Relief for Osteoarthritis Patients Benchmarked against Fish Oil a Randomized Trial without Placebo Control
【2h】

Perna canaliculus Lipid Complex PCSO-524™ Demonstrated Pain Relief for Osteoarthritis Patients Benchmarked against Fish Oil a Randomized Trial without Placebo Control

机译:Perna canaliculus脂质复合物PCSO-524™证明针对骨关节炎患者的镇痛效果以鱼油为基准这是一项随机试验无安慰剂对照

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Osteoarthritis (OA) typically generates pain, reduced mobility and reduced quality of life. Most conventional treatments for osteoarthritis, such as non-steroidal anti-inflammatory drugs (NSAIDs) and simple analgesics, have side effects. PCSO-524™, a non polar lipid extract from the New Zealand Green Lipped Mussel, is rich in omega-3 fatty acids and has been shown to reduce inflammation in both animal studies and patient trials. This OA trial examined pain relief changes in relation to quality of life and safety of use for OA patients who took PCSO-524™ compared with patients who took fish oil (containing an industry standard EPA-18% and DHA-12% blend). PCSO-524™ patients showed a statistically significant improvement compared with patients who took fish oil. There was an 89% decrease in their pain symptoms and 91% reported an improved quality of life. Patients treated with fish oil showed significantly less improvement and a greater level of physical discomfort during the study. These results suggest that PCSO-524™ might offer a potential alternative complementary therapy with no side effects for OA patients.
机译:骨关节炎(OA)通常会产生疼痛,行动不便和生活质量下降。骨关节炎的大多数常规疗法,例如非甾体类抗炎药(NSAID)和简单的镇痛药,都有副作用。 PCSO-524™是一种来自新西兰绿唇贻贝的非极性脂质提取物,富含omega-3脂肪酸,并且在动物研究和患者试验中均显示可减轻炎症。这项OA试验检查了服用PCSO-524™的OA患者与服用鱼油(含有行业标准EPA-18%和DHA-12%混合物的患者)相比,与生活质量和使用安全性相关的缓解疼痛的变化。与服用鱼油的患者相比,PCSO-524™患者表现​​出统计学上的显着改善。他们的疼痛症状减轻了89%,而91%的人的生活质量得到了改善。在研究期间,用鱼油治疗的患者表现出明显更少的改善和更大程度的身体不适。这些结果表明,PCSO-524™可能为OA患者提供潜在的替代性补充疗法,且无副作用。

著录项

相似文献

  • 外文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号